Jonathan Chang
Stock Analyst at Leerink Partners
(0.63)
# 3,883
Out of 4,876 analysts
86
Total ratings
30.14%
Success rate
-19.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMAB Genmab | Upgrades: Outperform | $27 | $20.50 | +31.71% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $31.15 | +137.56% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $4.53 | +143.03% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $18.00 | +183.33% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $4.33 | +1,632.10% | 12 | Jan 10, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $34 | $9.33 | +264.42% | 9 | Dec 7, 2022 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $7.21 | +593.48% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $36.90 | -18.70% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.19 | +908.40% | 8 | Aug 9, 2022 | |
| MRSN Mersana Therapeutics | Maintains: Outperform | $13 → $14 | $0.29 | +4,711.00% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $5.44 | +377.94% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $101 → $95 | $34.71 | +173.70% | 8 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.25 | +1,124.49% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $5.67 | +393.83% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $8.14 | +551.11% | 7 | Aug 5, 2021 |
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $20.50
Upside: +31.71%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $31.15
Upside: +137.56%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $4.53
Upside: +143.03%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $18.00
Upside: +183.33%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $4.33
Upside: +1,632.10%
Replimune Group
Dec 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $9.33
Upside: +264.42%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $7.21
Upside: +593.48%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $36.90
Upside: -18.70%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.19
Upside: +908.40%
Mersana Therapeutics
Aug 9, 2022
Maintains: Outperform
Price Target: $13 → $14
Current: $0.29
Upside: +4,711.00%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $5.44
Upside: +377.94%
May 11, 2022
Maintains: Outperform
Price Target: $101 → $95
Current: $34.71
Upside: +173.70%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.25
Upside: +1,124.49%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $5.67
Upside: +393.83%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $8.14
Upside: +551.11%